NIKKEI 225
25,979.75 -442.30 (-1.67%) HANG SENG
17,162.03 -3.84 (-0.02%) CRUDE OIL
81.10 -0.13 (-0.16%) GOLD FUTURES
1,670.70 +2.10 (+0.13%) DOW
29,225.61 -458.13 (-1.54%) BTC-GBP
17,493.44 -127.64 (-0.72%)
Atai Life Sciences N.V. (ATAI)
After hours:
| Previous close | 3.4000 |
| Open | 3.3600 |
| Bid | 3.2500 x 800 |
| Ask | 3.3000 x 1200 |
| Day's range | 3.1700 - 3.3600 |
| 52-week range | 2.9500 - 17.8100 |
| Volume | |
| Avg. volume | 785,149 |
| Market cap | 539.094M |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -1.3990 |
| Earnings date | 15 Aug 2022 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 23.96 |
- Globe Newswire
atai Life Sciences Announces Initiation of Phase 1 Trial for its MDMA Derivative, EMP-01
- atai’s wholly owned subsidiary, EmpathBio, has received Medsafe central regulatory and The Health and Disability Ethics Committees (HDEC) ethics approvals to initiate a Phase 1 trial to assess the safety and tolerability of orally administered EMP-01 in 32 healthy volunteers - EMP-01 is a 3,4-methylenedioxy-methamphetamine (MDMA) derivative under development for the treatment of post-traumatic stress disorder (PTSD) and other indications NEW YORK and BERLIN, Sept. 27, 2022 (GLOBE NEWSWIRE) --
- Globe Newswire
atai Life Sciences to Participate in September Investor Events
NEW YORK and BERLIN, Sept. 07, 2022 (GLOBE NEWSWIRE) -- atai Life Sciences N.V. (Nasdaq: ATAI) (“atai”), a clinical-stage biopharmaceutical company aiming to transform the treatment of mental health disorders, will participate in the following investor conferences in September: Citi’s 17th Annual BioPharma Conference in BostonFormat: Industry PanelDate and Time: Wednesday, September 7th, 10:30 a.m. ET – 11:15 a.m. ETConference Link: URL H.C. Wainwright’s 24th Annual Global Investment Conference
- Globe Newswire
atai Life Sciences Reports Second Quarter 2022 Financial Results & Business Update
- Added an anticipated additional year of runway into 2025 through securing non-dilutive debt facility from Hercules combined with execution of cost optimizations by prioritizing atai’s development programs with anticipated meaningful near-term clinical value inflections- Key achieved R&D milestones include completion of the clinical phase of the Drug-Drug-Interaction (DDI) study of PCN-101, database lock for the GRX-917 Phase 1 trial, completion of SAD portion of ongoing KUR-101 Phase 1 trial,
